Agenus | AGEN - Interest Expense On Debt


Agenus reported $14.67M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
AbbVie USD 688M 58M Sep/2026
Agenus USD 14.67M 1.35M Mar/2026
Amgen USD 653M 94.99B Sep/2026
AstraZeneca USD 371M 31M Sep/2026
Bristol-Myers Squibb USD 403M 4M Sep/2026
CSL USD 215M 111M Dec/2025
Eli Lilly USD 316M 201.3M Sep/2026
Gilead Sciences USD 269M 22M Sep/2026
GlaxoSmithKline GBP 219M 98M Sep/2026
Glaxosmithkline GBP 264.74M 72.01M Sep/2026
Incyte USD 605K 23K Sep/2026
Intrexon USD 2K 5K Jun/2024
J&J USD 43M 25M Mar/2026
Jiangsu Hengrui CNY 254.59M 253.85M Sep/2025
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
MacroGenics USD 4.4M 493K Jun/2026
Merck EUR 137M 33M Jun/2026
Merck USD 525M 46M Jun/2026
Northwest Biotherapeutics USD 1.52M 276K Mar/2024
Novartis USD 468M 6M Sep/2026
Novavax USD 5.82M 342K Dec/2025
Pfizer USD 662M 5M Sep/2026
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Rigel Pharmaceuticals USD 2.06M 31K Sep/2024
Sangamo BioSciences 97.56M 11.39M Jun/2025
Veracyte USD 2K 1000 Dec/2023